AzddMeC (Az-Dcme) is a nucleoside analog with antiviral activity and is an orally active and selective inhibitor of HIV-1 reverse transcriptase and HIV-1 replication.AzddMeC has an EC50 value of 9 nM against HIV-1-infected human PBM cells and 6 nM against HIV-1-infected human macrophages.

HIV-1:9 nM (EC50, Human PBM cells), HIV-1:6 nM (EC50, Human macrophages)

AzddMeC emerged as the most potent inhibitor of hepatitis B virus DNA polymerase (50% inhibitor dose, 0.03-0.35 μM). In contrast, cellular DNA polymerase was shown to be resistant to or partially (β) affected by AzddMeC. [4]

Following intravenously and orally administered 60 mg/kg AzddMeC to male rhesus monkeys, 3'-azido-3'-deoxythymidine (AZT) was found to be the major metabolite of AzddMeC in monkeys. Serum concentrations of AzddMeC decreased rapidly in a biexponential manner with terminal half-lives ranging from 0.5 to 1.3 h. Total clearance of AzddMeC was 2.00 +/- 0.41 l/h/kg (mean +/- standard deviation) and the fraction of AzddMeC metabolized to AZT was 0.32 +/- 0.05. The total clearance was 2.00 +/- 0.41 l/h/kg (mean +/- standard deviation).[2]